HHS, Pfizer, Reach Agreement to Ensure Access to Paxlovid

October 16, 2023 by Dan McCue
HHS, Pfizer, Reach Agreement to Ensure Access to Paxlovid
FILE - The anti-viral drug Paxlovid is displayed in New York, Monday, Aug. 1, 2022. (AP Photo/Stephanie Nano, File)

WASHINGTON — The Department of Health and Human Services announced last week that it has reached an agreement with Pfizer to ensure continued patient access to the antiviral Paxlovid as it prepares to transition the COVID treatment to the commercial market.

“This agreement builds on HHS and Pfizer’s strong partnership over the last three years that enabled the development, manufacture and distribution of COVID-19 vaccines and therapeutics at a record pace,” the department said in a written statement.

“HSS has consistently expressed a shared interest in jointly transitioning Paxlovid to the commercial market while ensuring that the United States taxpayer continues to receive fair and reasonable benefit from the [department’s] procurement of this product,” the statement continued.

Paxlovid was first authorized to treat COVID-19 in December 2021 and since then it has been distributed for free by the government. The drug’s transition to the commercial market is set to begin in November.

Under the terms of the agreement, individuals on Medicare, Medicaid and those who are uninsured will continue to be able to access HHS-procured Paxlovid for free through the end of 2024 via a patient assistance program. 

From 2025 to 2028, Pfizer will continue to run a patient assistance program for individuals who are uninsured or underinsured with HHS-procured Paxlovid. In parallel, Pfizer will operate a copay assistance program for individuals with commercial insurance through 2028.

Pfizer has agreed to continue to “refresh” the government’s inventory of Paxlovid through 2028, to make sure none of its supply is expired and that the department has the latest formulation. 

In addition, Pfizer will provide HHS with a stockpile of an additional 1 million treatment courses to ensure preparedness for future COVID-19 surges. 

Finally, to ensure a smooth and predictable transition to the commercial market over the next few months, Paxlovid will remain available for ordering from HHS through Dec. 15.

Dan can be reached at [email protected] and @DanMcCue

A+
a-
  • Department of Health and Human Services
  • HHS
  • Paxlovid
  • Pfizer
  • In The News

    Health

    Voting

    Health

    December 8, 2023
    by Dan McCue
    FDA Approves a CRISPR-Based Medicine to Treat Sickle Cell Disease

    WASHINGTON — The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology for... Read More

    WASHINGTON — The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology for the treatment of sickle cell disease. The new treatment, called Casgevy, was manufactured by Vertex Pharmaceuticals, of Boston, Massachusetts, and CRISPR Therapeutics, of Switzerland, using a... Read More

    Chronic Fatigue Syndrome More Common Than Past Studies Suggest, CDC Says

    NEW YORK (AP) — Health officials on Friday released the first nationally representative estimate of how many U.S. adults have... Read More

    NEW YORK (AP) — Health officials on Friday released the first nationally representative estimate of how many U.S. adults have chronic fatigue syndrome: 3.3 million. The Centers for Disease Control and Prevention's number is larger than previous studies have suggested, and is likely boosted by some... Read More

    December 8, 2023
    by Tom Ramstack
    White House Threatens to Penalize Pharma Companies for High Prices

    WASHINGTON — The Biden administration announced a plan Thursday to lower prescription drug costs in a move that takes a... Read More

    WASHINGTON — The Biden administration announced a plan Thursday to lower prescription drug costs in a move that takes a tough stance toward pharmaceutical companies charging high prices. If the Federal Trade Commission determines the prices are unreasonable, the new policy allows the federal government to... Read More

    December 6, 2023
    by Dan McCue
    House Unanimously Passes Bill to Increase Mental Health Resources for Veterans’ Caregivers

    WASHINGTON — The House on Monday unanimously passed the Caregiver Outreach and Program Enhancement Act, which would increase mental health... Read More

    WASHINGTON — The House on Monday unanimously passed the Caregiver Outreach and Program Enhancement Act, which would increase mental health resources available to caregivers of America’s veteran population. Alternately known as the COPE Act, the bipartisan legislation sponsored by Reps. Chrissy Houlahan, D-Pa., and Jen Kiggans,... Read More

    December 6, 2023
    by Dan McCue
    HHS Unveils Next Steps to Enhance Cybersecurity of Health Care Records

    WASHINGTON — The bad guys in cyberspace want your health care records.  Between 2018 and 2022, there was a 93%... Read More

    WASHINGTON — The bad guys in cyberspace want your health care records.  Between 2018 and 2022, there was a 93% increase in large breaches in the health care sector, with a 278% increase in large breaches involving ransomware, according to the Department of Health and Human... Read More

    December 6, 2023
    by Dan McCue
    New Report Sheds Some Light on Rare Post-COVID Shot Syndrome

    NEW HAVEN, Conn. — A study from the Yale School of Medicine sheds some new light on the rare, but... Read More

    NEW HAVEN, Conn. — A study from the Yale School of Medicine sheds some new light on the rare, but chronic and debilitating condition some people report experiencing after getting a COVID-19 vaccination. The paper, which was posted on the preprint server medRxiv and has not... Read More

    News From The Well
    scroll top